BACKGROUND: Right heart failure (RHF) is an unresolved issue during continuous-flow left ventricular assist device (LVAD) support. Little is known about post-transplant outcomes in patients complicated by late RHF during LVAD support. METHODS: Between May 2004 and December 2013, 141 patients underwent cardiac transplantation after isolated LVAD bridging at our center. Late RHF was defined as heart failure requiring medical intervention >4 weeks after LVAD implantation. RESULTS: The patients' mean age was 53 ± 13 years, 82% were men, and 36% had an ischemic etiology. The mean duration of LVAD support before transplantation was 0.75 years. Late RHF developed in 21 patients (15%) during LVAD support. Of these patients, 11 were supported with inotropic agents at the time of transplantation. Patients with RHF had higher creatinine (1.6 ± 0.88 mg/dL vs 1.3 ± 0.67 mg/dL, p = 0.07), higher blood urea nitrogen (32 ± 17 mg/dL vs 24 ± 10 mg/dL, p = 0.0013), higher total bilirubin (0.96 ± 0.46 mg/dL vs 0.78 ± 0.42 mg/dL, p = 0.07), and lower albumin (3.8 ± 0.60 g/dL vs 4.1 ± 0.46 g/dL, p = 0.0019) at the time of transplantation compared with patients who did not develop RHF. In-hospital mortality was significantly higher in patients with late RHF during LVAD support (29% vs 6.7%, p = 0.002). Overall post-transplant survival rates were 87% at 1 year, 83% at 3 years, and 77% at 5 years. The 5-year post-transplant survival was significantly worse in patients who developed late RHF during LVAD support compared with survival in patients who did not develop RHF (26% vs 87%, p < 0.0001). CONCLUSIONS: Late RHF during LVAD support adversely affects post-transplant survival. Published by Elsevier Inc.
BACKGROUND:Right heart failure (RHF) is an unresolved issue during continuous-flow left ventricular assist device (LVAD) support. Little is known about post-transplant outcomes in patients complicated by late RHF during LVAD support. METHODS: Between May 2004 and December 2013, 141 patients underwent cardiac transplantation after isolated LVAD bridging at our center. Late RHF was defined as heart failure requiring medical intervention >4 weeks after LVAD implantation. RESULTS: The patients' mean age was 53 ± 13 years, 82% were men, and 36% had an ischemic etiology. The mean duration of LVAD support before transplantation was 0.75 years. Late RHF developed in 21 patients (15%) during LVAD support. Of these patients, 11 were supported with inotropic agents at the time of transplantation. Patients with RHF had higher creatinine (1.6 ± 0.88 mg/dL vs 1.3 ± 0.67 mg/dL, p = 0.07), higher blood urea nitrogen (32 ± 17 mg/dL vs 24 ± 10 mg/dL, p = 0.0013), higher total bilirubin (0.96 ± 0.46 mg/dL vs 0.78 ± 0.42 mg/dL, p = 0.07), and lower albumin (3.8 ± 0.60 g/dL vs 4.1 ± 0.46 g/dL, p = 0.0019) at the time of transplantation compared with patients who did not develop RHF. In-hospital mortality was significantly higher in patients with late RHF during LVAD support (29% vs 6.7%, p = 0.002). Overall post-transplant survival rates were 87% at 1 year, 83% at 3 years, and 77% at 5 years. The 5-year post-transplant survival was significantly worse in patients who developed late RHF during LVAD support compared with survival in patients who did not develop RHF (26% vs 87%, p < 0.0001). CONCLUSIONS: Late RHF during LVAD support adversely affects post-transplant survival. Published by Elsevier Inc.
Authors: Bastian Schmack; Alexander Weymann; Frank Ruschitzka; Rüdiger Autschbach; Philip W Raake; Nadine Jurrmann; Ares K Menon; Matthias Karck; Markus J Wilhelm; Arjang Ruhparwar Journal: Clin Res Cardiol Date: 2018-01-02 Impact factor: 5.460
Authors: Chris J Kapelios; Lars H Lund; Omar Wever-Pinzon; Craig H Selzman; Susan L Myers; Ryan S Cantor; Josef Stehlik; Themistocles Chamogeorgakis; Stephen H McKellar; Antigone Koliopoulou; Rami Alharethi; Abdallah G Kfoury; Michael Bonios; Stamatis Adamopoulos; Edward M Gilbert; James C Fang; James K Kirklin; Stavros G Drakos Journal: Circ Heart Fail Date: 2022-06-06 Impact factor: 10.447
Authors: Mark S Goodin; Michael S Showalter; David J Horvath; Barry D Kuban; Christine R Flick; Anthony R Polakowski; Kiyotaka Fukamachi; Jamshid H Karimov Journal: ASAIO J Date: 2021-11-10 Impact factor: 3.826
Authors: Yaron D Barac; Alina Nicoara; Muath Bishawi; Jacob N Schroder; Mani A Daneshmand; Nazish K Hashmi; Eric Velazquez; Joseph G Rogers; Chetan B Patel; Carmelo A Milano Journal: JACC Heart Fail Date: 2019-12-11 Impact factor: 12.035
Authors: Toshinobu Kazui; Phat L Tran; Angela Echeverria; Catherine F Jerman; Jessika Iwanski; Samuel S Kim; Richard G Smith; Zain I Khalpey Journal: J Cardiothorac Surg Date: 2016-08-04 Impact factor: 1.637
Authors: Tobias Wagner; Alexander M Bernhardt; Christina Magnussen; Hermann Reichenspurner; Stefan Blankenberg; Hanno Grahn Journal: J Cardiothorac Surg Date: 2020-05-25 Impact factor: 1.637
Authors: Moritz Benjamin Immohr; Udo Boeken; Franziska Mueller; Emir Prashovikj; Michiel Morshuis; Charlotte Böttger; Hug Aubin; Jan Gummert; Payam Akhyari; Artur Lichtenberg; René Schramm Journal: ESC Heart Fail Date: 2021-01-21